left ventricular diastolic dysfunction; heart failure with preserved ejection fraction (HFpEF)

From Aaushi
Jump to navigation Jump to search

Etiology

* implantable defibrillator is a negative risk factor[34]

Epidemiology

Pathology

Clinical manifestations

Laboratory

Diagnostic procedures

* Early to Atrial ratio

Complications

Differential diagnosis

Management

* rationale is that poor nitric oxide availability may play role in LV diastolic dysfunction[50]

More general terms

Additional terms

References

  1. nlmpubs.nlm.nih.gov/hstat/ahcpr/
  2. Harrison's Principles of Internal Medicine, 14th ed. Fauci et al (eds), McGraw-Hill Inc. NY, 1998, pg 1296
  3. 3.0 3.1 3.2 3.3 3.4 3.5 3.6 3.7 Medical Knowledge Self Assessment Program (MKSAP) 11, 14, 16, 18, 19. American College of Physicians, Philadelphia 1998, 2006, 2012, 2018, 2022
    Medical Knowledge Self Assessment Program (MKSAP) 19 Board Basics. An Enhancement to MKSAP19. American College of Physicians, Philadelphia 2022
  4. Watson K, in: UCLA Intensive Course in Geriatric Medicine & Board Review, Marina Del Ray, CA, Sept 12-15, 2001
  5. 5.0 5.1 Gottdiener JS et al Outcome of congestive heart failure in elderly persons: influence of left ventricular systolic function. The Cardiovascular Health Study. Ann Intern Med 137:631, 2002 PMID: https://www.ncbi.nlm.nih.gov/pubmed/12379062
  6. 6.0 6.1 Redfield MM et al Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA 289:194, 2003 PMID: https://www.ncbi.nlm.nih.gov/pubmed/12517230
  7. 7.0 7.1 7.2 7.3 7.4 7.5 7.6 7.7 UpToDate version 12.2
  8. 8.0 8.1 8.2 Bhatia RS et al, Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med 2006; 355:260 PMID: https://www.ncbi.nlm.nih.gov/pubmed/16855266
  9. 9.0 9.1 Lee DS, Pencina MJ, Benjamin EJ, Wang TJ, Levy D, O'Donnell CJ, Nam BH, Larson MG, D'Agostino RB, Vasan RS. Association of parental heart failure with risk of heart failure in offspring. N Engl J Med. 2006 Jul 13;355(2):138-47. PMID: https://www.ncbi.nlm.nih.gov/pubmed/16837677
  10. Bhatia RS, Tu JV, Lee DS, Austin PC, Fang J, Haouzi A, Gong Y, Liu PP. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med. 2006 Jul 20;355(3):260-9. PMID: https://www.ncbi.nlm.nih.gov/pubmed/16855266
  11. Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med. 2006 Jul 20;355(3):251-9. PMID: https://www.ncbi.nlm.nih.gov/pubmed/16855265
  12. Aurigemma GP. Diastolic heart failure--a common and lethal condition by any name. N Engl J Med. 2006 Jul 20;355(3):308-10. No abstract available. PMID: https://www.ncbi.nlm.nih.gov/pubmed/16855273 Aurigemma GP, Gaasch WH Diastolic Heart Failure N Engl J Med 2004; 351:1097-1105. September 9, 2004 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/15356307 <Internet> http://www.nejm.org/doi/full/10.1056/NEJMcp022709
  13. 13.0 13.1 Ahmed A, Rich MW, Fleg JL, Zile MR, Young JB, Kitzman DW, Love TE, Aronow WS, Adams KF Jr, Gheorghiade M. Effects of digoxin on morbidity and mortality in diastolic heart failure: the ancillary digitalis investigation group trial. Circulation. 2006 Aug 1;114(5):397-403. Epub 2006 Jul 24. PMID: https://www.ncbi.nlm.nih.gov/pubmed/16864724
  14. 14.0 14.1 Cleland JG et al, The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Hear J 2006, 27:2338 PMID: https://www.ncbi.nlm.nih.gov/pubmed/16963472
    McMurray J Renin angiotensin blockade in heart failure with preserved ejection fraction: The signal gets stronger. Eur Hear J 2006, 27:2257 PMID: https://www.ncbi.nlm.nih.gov/pubmed/16963471
  15. 15.0 15.1 15.2 Bursi F et al, Systolic and diastolic heart failure in the community. JAMA 2006, 296:2209 http://jama.ama-assn.org/cgi/content/full/296/18/2209
    Hildebrandt P, Systolic and nonsystolic heart failure: Equally serious threats JAMA 2006, 296:2259 http://jama.ama-assn.org/cgi/content/full/296/18/2259
  16. 16.0 16.1 Solomon SD et al. Effect of angiotensin receptor blockade and antihypertensive drugs on diastolic function in patients with hypertension and diastolic dysfunction: A randomised trial. Lancet 2007 Jun 23; 369:2079-87 PMID: https://www.ncbi.nlm.nih.gov/pubmed/17586303
    Ahmed A et al. VALIDD should not invalidate angiotensin-receptor blockers. Lancet 2007 Jun 23; 369:2053-4 PMID: https://www.ncbi.nlm.nih.gov/pubmed/17586284
  17. 17.0 17.1 Massie BM et al. for the I-PRESERVE Investigators. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 2008 Nov 11; [e-pub ahead of print] <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/19001508 <Internet> http://dx.doi.org/10.1056/NEJMoa0805450
  18. Prescriber's Letter 16(1): 2009 Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=250126&pb=PRL (subscription needed) http://www.prescribersletter.com
  19. Grewal J et al. Left ventricular function and exercise capacity. JAMA 2009 Jan 21; 301:286. PMID: https://www.ncbi.nlm.nih.gov/pubmed/19155455
  20. 20.0 20.1 van Veldhuisen DJ et al. Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: Data from SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure). J Am Coll Cardiol 2009 Jun 9; 53:2150. PMID: https://www.ncbi.nlm.nih.gov/pubmed/19497441
  21. 21.0 21.1 Zile MR et al. Mode of death in patients with heart failure and a preserved ejection fraction: Results from the Irbesartan in Heart Failure with Preserved Ejection Fraction Study (I-Preserve) trial. Circulation 2010 Mar 30; 121:1393. PMID: https://www.ncbi.nlm.nih.gov/pubmed/20231531
  22. 22.0 22.1 22.2 Russo C et al. Effect of obesity and overweight on left ventricular diastolic function: A community-based study in an elderly cohort. J Am Coll Cardiol 2011 Mar 22; 57:1368. PMID: https://www.ncbi.nlm.nih.gov/pubmed/21414533
  23. Kane GC et al. Progression of left ventricular diastolic dysfunction and risk of heart failure. JAMA 2011 Aug 24/31; 306:856. PMID: https://www.ncbi.nlm.nih.gov/pubmed/21862747
  24. 24.0 24.1 24.2 24.3 24.4 24.5 24.6 Geriatric Review Syllabus, 7th edition Parada JT et al (eds) American Geriatrics Society, 2010
    Geriatric Review Syllabus, 8th edition (GRS8) Durso SC and Sullivan GN (eds) American Geriatrics Society, 2013
    Geriatric Review Syllabus, 9th edition (GRS9) Medinal-Walpole A, Pacala JT, Porter JF (eds) American Geriatrics Society, 2016
    Geriatric Review Syllabus, 10th edition (GRS10) Harper GM, Lyons WL, Potter JF (eds) American Geriatrics Society, 2019
    Geriatric Review Syllabus, 11th edition (GRS11) Harper GM, Lyons WL, Potter JF (eds) American Geriatrics Society, 2022
  25. 25.0 25.1 Lund LH et al Association Between Use of Renin-Angiotensin System Antagonists and Mortality in Patients With Heart Failure and Preserved Ejection Fraction. JAMA. 2012;308(20):2108-2117 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/23188027 <Internet> http://jama.jamanetwork.com/article.aspx?articleid=1456058
    Fang JC. Heart failure therapy: What should clinicians believe? JAMA 2012 Nov 28; 308:2144. PMID: https://www.ncbi.nlm.nih.gov/pubmed/23188032
  26. 26.0 26.1 Edelmann F et al Effect of Spironolactone on Diastolic Function and Exercise Capacity in Patients With Heart Failure With Preserved Ejection Fraction. The Aldo-DHF Randomized Controlled Trial. JAMA. 2013;309(8):781-791 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/23443441 <Internet> http://jama.jamanetwork.com/article.aspx?articleid=1656252
    Cleland JGF and Pellicori P Defining Diastolic Heart Failure and Identifying Effective Therapies. JAMA. 2013;309(8):825-826. <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/23443447 <Internet> http://jama.jamanetwork.com/article.aspx?articleid=1656233
  27. 27.0 27.1 Redfield MM et al Effect of Phosphodiesterase-5 Inhibition on Exercise Capacity and Clinical Status in Heart Failure With Preserved Ejection Fraction. A Randomized Clinical Trial. JAMA. 2013;():1-10. <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/23478662 <Internet> http://jama.jamanetwork.com/article.aspx?articleid=1663257
  28. 28.0 28.1 Loffredo FS et al. Growth differentiation factor 11 is a circulating factor that reverses age-related cardiac hypertrophy. Cell 2013 May 9; 153:828 PMID: https://www.ncbi.nlm.nih.gov/pubmed/23663781
  29. Paulus WJ, van Ballegoij JJ. Treatment of heart failure with normal ejection fraction: an inconvenient truth! J Am Coll Cardiol. 2010 Feb 9;55(6):526-37. PMID: https://www.ncbi.nlm.nih.gov/pubmed/20152557
  30. Chen MA Heart failure with preserved ejection fraction in older adults. Am J Med. 2009 Aug;122(8):713-23 PMID: https://www.ncbi.nlm.nih.gov/pubmed/19635270
  31. 31.0 31.1 Pitt B, Pfieffer MA, Assmann SF et al Spironolactone for Heart Failure with Preserved Ejection Fraction. N Engl J Med 2014; 370:1383-1392April 10, 2014 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/24716680 <Internet> http://www.nejm.org/doi/full/10.1056/NEJMoa1313731
  32. 32.0 32.1 Mujib M, Patel K, Fonarow GC, et. al. Angiotensin-converting enzyme inhibitors and outcomes in heart failure and preserved ejection fraction. Am J Med. 2013;126:401-410. PMID: https://www.ncbi.nlm.nih.gov/pubmed/23510948
  33. 33.0 33.1 Ahmed A, Rich MW, Zile M, et. al. Renin-angiotensin inhibition in diastolic heart failure and chronic kidney disease. Am J Med. 2013;126:150-161. PMID: https://www.ncbi.nlm.nih.gov/pubmed/2333144
  34. 34.0 34.1 34.2 34.3 Gurwitz JH, Magid DJ, Smith DH, et al. Contemporary prevalence and correlates of incident heart failure with preserved ejection fraction. Am J Med. 2013;126:393-400 PMID: https://www.ncbi.nlm.nih.gov/pubmed/23499328
  35. Meyer T, Shih J, Aurigemma G. Heart failure with preserved ejection fraction (diastolic dysfunction). Ann Intern Med. 2013;158(1):ITC1-1. PMID: https://www.ncbi.nlm.nih.gov/pubmed/23277912
  36. 36.0 36.1 Rosendorff C et al. Treatment of hypertension in patients with coronary artery disease: A scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension. J Am Coll Cardiol 2015 May 12; 65:1998 PMID: https://www.ncbi.nlm.nih.gov/pubmed/25840655
  37. 37.0 37.1 37.2 Edelmann F et al. Tolerability and feasibility of beta-blocker titration in HFpEF versus HFrEF: Insights from the CIBIS-ELD trial. JACC Heart Fail 2015 Dec 6 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/26682793 <Internet> http://www.sciencedirect.com/science/article/pii/S2213177915006976
  38. 38.0 38.1 Kitzman DW et al. Effect of caloric restriction or aerobic exercise training on peak oxygen consumption and quality of life in obese older patients with heart failure with preserved ejection fraction: A randomized clinical trial. JAMA 2016 Jan 5; 315:36. PMID: https://www.ncbi.nlm.nih.gov/pubmed/26746456
    Wenger NK. Lifestyle interventions to improve exercise tolerance in obese older patients with heart failure and preserved ejection fraction. JAMA. 2016 Jan 5;315(1):31-3 PMID: https://www.ncbi.nlm.nih.gov/pubmed/26746454
  39. Steinberg BA, Zhao X, Heidenreich PA et al Trends in patients hospitalized with heart failure and preserved left ventricular ejection fraction: prevalence, therapies, and outcomes. Circulation. 2012 Jul 3;126(1):65-75. PMID: https://www.ncbi.nlm.nih.gov/pubmed/22615345 Free Article
  40. 40.0 40.1 40.2 40.3 Redfield MM Heart Failure with Preserved Ejection Fraction. N Engl J Med 2016; 375:1868-1877. November 10, 2016 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/27959663 <Internet> http://www.nejm.org/doi/full/10.1056/NEJMcp1511175
  41. 41.0 41.1 41.2 41.3 41.4 Yamamoto K. Pharmacological Treatment of Heart Failure with Preserved Ejection Fraction. Yonago Acta Med. 2017 Jun 26;60(2):71-76. Review. PMID: https://www.ncbi.nlm.nih.gov/pubmed/28701888 Free PMC Article
  42. Oren O, Goldberg S. Heart Failure with Preserved Ejection Fraction: Diagnosis and Management. Am J Med. 2017 May;130(5):510-516. Epub 2017 Feb 3. Review. PMID: https://www.ncbi.nlm.nih.gov/pubmed/28163048
  43. 43.0 43.1 Vaduganathan M, Patel RB, Michel A et al. Mode of Death in Heart Failure With Preserved Ejection Fraction. J Am Coll Cardiol. 2017 Feb 7;69(5):556-569. Review PMID: https://www.ncbi.nlm.nih.gov/pubmed/28153111
  44. 44.0 44.1 Polsinelli VB, Shah SJ. Advances in the pharmacotherapy of chronic heart failure with preserved ejection fraction: an ideal opportunity for precision medicine. Expert Opin Pharmacother. 2017 Mar;18(4):399-409. Review. PMID: https://www.ncbi.nlm.nih.gov/pubmed/28129699
  45. Upadhya B, Pisani B, Kitzman DW Evolution of a Geriatric Syndrome: Pathophysiology and Treatment of Heart Failure With Preserved Ejection Fraction. J Am Geriatr Soc. 2017 Nov;65(11):2431-2440 PMID: https://www.ncbi.nlm.nih.gov/pubmed/29124734
  46. 46.0 46.1 46.2 Zheng SL, Chan FT, Nabeebaccus AA et al. Drug treatment effects on outcomes in heart failure with preserved ejection fraction: A systematic review and meta- analysis. Heart 2017 Aug 5; pii: heartjnl-2017-311652 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/28780577 Free Article <Internet> http://heart.bmj.com/content/early/2017/08/03/heartjnl-2017-311652
    Van Spall HGC. Review: In HF with preserved EF, beta-blockers reduced mortality; drug treatment overall did not. Ann Intern Med 2017 Dec 19; 167:JC68 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/29255858 <Internet> http://annals.org/aim/article-abstract/2666325/review-hf-preserved-ef-blockers-reduced-mortality-drug-treatment-overall
  47. 47.0 47.1 Tsimploulis A, Lam PH, Arundel C et al Systolic Blood Pressure and Outcomes in Patients With Heart Failure With Preserved Ejection Fraction. JAMA Cardiol. Published online Feb 14, 2018 PMID: https://www.ncbi.nlm.nih.gov/pubmed/29450487 https://jamanetwork.com/journals/jamacardiology/article-abstract/2672572
  48. 48.0 48.1 Vanderpool RR, Saul M, Nouraie M, Gladwin MT, Simon MA. Association Between Hemodynamic Markers of Pulmonary Hypertension and Outcomes in Heart Failure With Preserved Ejection Fraction. JAMA Cardiol. Published online March 14, 2018 PMID: https://www.ncbi.nlm.nih.gov/pubmed/29541759 https://jamanetwork.com/journals/jamacardiology/fullarticle/2674721
  49. Reddy YNV, Carter RE, Obokata M et al. A simple, evidence-based approach to help guide diagnosis of heart failure with preserved ejection fraction. Circulation 2018 Aug 28; 138:861 PMID: https://www.ncbi.nlm.nih.gov/pubmed/29792299 https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.118.034646
  50. 50.0 50.1 50.2 Borlaug BA, Anstrom KJ, Lewis GD et al. Effect of inorganic nitrite vs placebo on exercise capacity among patients with heart failure with preserved ejection fraction: The INDIE-HFpEF randomized clinical trial. JAMA 2018 Nov 6; 320:1764. PMID: https://www.ncbi.nlm.nih.gov/pubmed/30398602 https://jamanetwork.com/journals/jama/article-abstract/2712543
  51. 51.0 51.1 Merrill M, Sweitzer NK, Lindenfeld J, Kao DP. Sex differences in outcomes and responses to spironolactone in heart failure with preserved ejection fraction: A secondary analysis of TOPCAT trial. JACC Heart Fail 2019 Mar; 7:228-238 PMID: https://www.ncbi.nlm.nih.gov/pubmed/30819379 https://www.sciencedirect.com/science/article/pii/S2213177919300095
  52. 52.0 52.1 Balmforth C, Simpson J, Shen L et al. Outcomes and effect of treatment according to etiology in HFrEF: An analysis of PARADIGM-HF. JACC Heart Fail 2019 Jun; 7:457. PMID: https://www.ncbi.nlm.nih.gov/pubmed/31078482 Free full text https://www.sciencedirect.com/science/article/pii/S2213177919301702
    Udelson JE. Is heart failure etiology destiny? Outcome and therapeutic implications. JACC Heart Fail 2019 Jun; 7:466. PMID: https://www.ncbi.nlm.nih.gov/pubmed/31078474 https://www.sciencedirect.com/science/article/pii/S2213177919302367
  53. 53.0 53.1 Beggs SAS, Rorth R, Gardner RS, McMurray JJV. Anticoagulation therapy in heart failure and sinus rhythm: A systematic review and meta-analysis. Heart 2019 Sep; 105:1325. PMID: https://www.ncbi.nlm.nih.gov/pubmed/30962190 https://heart.bmj.com/content/105/17/1325
  54. 54.0 54.1 Lou N A Small Step for Olive Oil as HFpEF Treatment - Small CPET improvements suggested by preliminary diet study. MedPage Today October 4, 2020 https://www.medpagetoday.com/meetingcoverage/hfsa/88946
    Billingsley H, et al Dietary supplementation of extra virgin olive oil in patients w with heart failure with preserved ejection fraction is associated with increases in cardiorespiratory fitness Heart Failure Society of Amertica (HFSA) 2020
  55. Armstrong PW et al. Effect of vericiguat vs placebo on quality of life in patients with heart failure and preserved ejection fraction: The VITALITY-HFpEF randomized clinical trial. JAMA 2020 Oct 20; 324:1512. PMID: https://www.ncbi.nlm.nih.gov/pubmed/33079152 https://jamanetwork.com/journals/jama/article-abstract/2771900
    Udelson JE et al. Effect of praliciguat on peak rate of oxygen consumption in patients with heart failure with preserved ejection fraction: The CAPACITY HFpEF randomized clinical trial. JAMA 2020 Oct 20; 324:1522. PMID: https://www.ncbi.nlm.nih.gov/pubmed/33079154 https://jamanetwork.com/journals/jama/article-abstract/2771902
  56. 56.0 56.1 56.2 Mueller S, Winzer EB, Duvinage A et al Effect of High-Intensity Interval Training, Moderate Continuous Training, or Guideline-Based Physical Activity Advice on Peak Oxygen Consumption in Patients With Heart Failure With Preserved Ejection FractionA Randomized Clinical Trial. JAMA. 2021;325(6):542-551. Feb 9 PMID: https://www.ncbi.nlm.nih.gov/pubmed/33560320 https://jamanetwork.com/journals/jama/fullarticle/2776199
  57. 57.0 57.1 57.2 Faselis C, Lam PH, Zile MR et al. Systolic blood pressure and outcomes in older patients with HFpEF and hypertension. Am J Med 2021 Apr 1; 134:e252. PMID: https://www.ncbi.nlm.nih.gov/pubmed/33010225 https://www.amjmed.com/article/S0002-9343(20)30812-3/fulltext
  58. 58.0 58.1 Zhou H et al beta-blocker use and risk of mortality in heart failure patients initiating maintenance dialysis. Am J Kidney Dis 2021 May; 77:704 PMID: https://www.ncbi.nlm.nih.gov/pubmed/33010357 https://www.ajkd.org/article/S0272-6386(20)31001-5/fulltext
  59. 59.0 59.1 59.2 Ferreira JP, Rossello X, Pocock SJ et al. Spironolactone dose in heart failure with preserved ejection fraction: findings from TOPCAT. Eur J Heart Fail. 2020;22(9):1615-1624 PMID: https://www.ncbi.nlm.nih.gov/pubmed/32452128 https://onlinelibrary.wiley.com/doi/10.1002/ejhf.1909
    Kalogeropoulos AP, Thankachen J, Butler J et al. Diuretic and renal effects of spironolactone and heart failure hospitalizations: a TOPCAT Americas analysis. Eur J Heart Fail. 2020;22(9):1600-1610 PMID: https://www.ncbi.nlm.nih.gov/pubmed/32469156 https://onlinelibrary.wiley.com/doi/10.1002/ejhf.1917
  60. Heidenreich PA et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure. J Am Coll Cardiol 2022 Apr 1; [e-pub] PMID: https://www.ncbi.nlm.nih.gov/pubmed/35363499 Review. https://www.sciencedirect.com/science/article/abs/pii/S0735109721083959
  61. 61.0 61.1 Li J et al. Salt restriction and risk of adverse outcomes in heart failure with preserved ejection fraction. Heart 2022 Jul 18; [e-pub] PMID: https://www.ncbi.nlm.nih.gov/pubmed/35851318 https://heart.bmj.com/content/early/2022/06/07/heartjnl-2022-321167
  62. 62.0 62.1 Anker SD, Butler J, Filippatos G et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med 2021. Oct 14;385(16):1451-1461. Aug 27; [e-pub] PMID: https://www.ncbi.nlm.nih.gov/pubmed/34449189 https://www.nejm.org/doi/10.1056/NEJMoa2107038
    Butler J, Filippatos G, Siddiqi TJ et al Empagliflozin, health status, and quality of life in patients with heart failure and preserved ejection fraction: The EMPEROR-Preserved Trial. Circulation 2021 Nov 15; [e-pub]. PMID: https://www.ncbi.nlm.nih.gov/pubmed/34779658 Free article https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.121.057812
    Solomon SD et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med 2022 Aug 27; [e-pub]. PMID: https://www.ncbi.nlm.nih.gov/pubmed/36027570 https://www.nejm.org/doi/10.1056/NEJMoa2206286
  63. 63.0 63.1 Reddy YNV et al. Diagnosis of heart failure with preserved ejection fraction among patients with unexplained dyspnea. JAMA Cardiol 2022 Sep; 7:891. PMID: https://www.ncbi.nlm.nih.gov/pubmed/35830183 PMCID: PMC9280610 (available on 2023-07-13) https://jamanetwork.com/journals/jamacardiology/fullarticle/2793877
  64. 64.0 64.1 Andersen MJ, Borlaug BA Heart failure with preserved ejection fraction: current understandings and challenges. Curr Cardiol Rep. 2014 Jul;16(7):501. PMID: https://www.ncbi.nlm.nih.gov/pubmed/24893938
  65. Redfield MM, Borlaug BA Heart Failure With Preserved Ejection Fraction. A Review. JAMA. 2023;329(10):827-838 PMID: https://www.ncbi.nlm.nih.gov/pubmed/36917048 https://jamanetwork.com/journals/jama/fullarticle/2802310
  66. 66.0 66.1 66.2 Kittleson MM et al. 2023 ACC expert consensus decision pathway on management of heart failure with preserved ejection fraction: A report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol 2023 May; 81:1835. PMID: https://www.ncbi.nlm.nih.gov/pubmed/37137593 https://www.sciencedirect.com/science/article/pii/S0735109723050982
  67. 67.0 67.1 Vaduganathan M, Mentz RJ, Claggett BL et al Sacubitril/valsartan in heart failure with mildly reduced or preserved ejection fraction: a pre-specified participant-level pooled analysis of PARAGLIDE-HF and PARAGON-HF. Eur Heart J. 2023 Aug 14;44(31):2982-2993. PMID: https://www.ncbi.nlm.nih.gov/pubmed/37210743 PMCID: PMC10424880 Free PMC article. Clinical Trial.
  68. 68.0 68.1 68.2 NEJM Knowledge+